PDF(Pubmed)
Abstract：
Osmoprotectant osmolyte and nonsteroidal anti-inflammatory drug (NSAID) coadministration can work synergistically in cancer chemotherapy since most tumors are inflammatory and cancer cells experience osmotic stress. NSAIDs have been shown to inhibit cyclooxygenase (COX) enzymes, which in turn reduces prostaglandin synthesis and prevents inflammation. They also encourage cell death to prevent tumor growth and its spread to other tissues and prevent the construction of new blood vessels, which contributes to the growth of cancer. Taurine belongs to the class of osmolytes since it has been shown to stabilize macromolecular structures and maintain cellular osmotic balance when combined with betaine and glycine. When these drugs are taken together, as opposed to separately, the effectiveness of cancer treatment is increased by increasing cancer cell death and suppressing tumor growth. Notable therapeutic benefits include the reduction of local inflammatory milieu by NSAIDs, which promotes tumor development, and the protection of surviving, normal cells and tissues from treatment-induced damage caused by cancer. By enhancing this synergy, side-effect risk can be decreased and treatment outcomes improved in terms of quality. Put another way, peptides can increase the therapeutic index of NSAIDs in cancer patients by preventing cell damage, which may lessen the gastrointestinal (GI), cardiovascular (CV), and renal side effects of the drug. However, there are drawbacks because using NSAIDs for an extended period of time is linked to serious side effects that call for strict supervision. More research is required because the usefulness and significance of osmolytes in cancer therapy are still very unclear, if not fragmented. In addition, people who live in places with limited resources may find it difficult to afford the possible expenditures associated with osmolytes and selective cyclooxygenase-2 (COX-2) inhibitors. Only the molecular mechanisms of the two drugs\' interactions, the appropriate dosages for combination therapy, and clinical trials to validate the efficacy and safety of this dosage should be the focus of future research. The request is inviting because it presents hope for an extremely successful antiviral strategy; nevertheless, in order to implement this approach successfully, it is likely to be necessary to create affordable formulations and scalable solutions that do not necessitate excessive treatment regimen individualization. Due to their complementary capacities to demonstrate anti-inflammatory and cytoprotective effects, Akta and 5-aminosalicylic acid (5-ASA) administration may thus represent a significant advancement in the treatment of cancer.
摘要：
渗透保护剂渗透压和非甾体抗炎药（NSAID）共同给药可以在癌症化疗中协同作用，因为大多数肿瘤是炎性的，癌细胞经历渗透应激。NSAIDs已显示抑制环氧合酶（COX）酶，这反过来减少前列腺素合成并防止炎症。它们还鼓励细胞死亡，以防止肿瘤生长及其扩散到其他组织，并防止新血管的构建，这有助于癌症的生长。牛磺酸属于渗透压物质类别,因为其已显示当与甜菜碱和甘氨酸组合时稳定大分子结构并维持细胞渗透平衡。当这些药物一起服用时，而不是分开，通过增加癌细胞死亡和抑制肿瘤生长来提高癌症治疗的有效性。显著的治疗益处包括通过NSAIDs减少局部炎症环境,促进肿瘤发展，和生存的保护，正常细胞和组织由治疗引起的癌症引起的损伤。通过增强这种协同作用，副作用风险可以降低,治疗结果在质量方面有所改善.换句话说，肽可以通过预防细胞损伤来增加NSAIDs在癌症患者中的治疗指数，这可能会减少胃肠道（GI），心血管（CV），和药物的肾脏副作用。然而,存在缺点,因为长时间使用NSAIDs与需要严格监管的严重副作用有关.需要更多的研究，因为渗透调节物质在癌症治疗中的有用性和意义仍不清楚，如果不是支离破碎的。此外,生活在资源有限的地方的人可能会发现难以负担与渗透压和选择性环氧合酶-2(COX-2)抑制剂相关的可能支出.只有两种药物相互作用的分子机制，联合治疗的适当剂量，和临床试验验证该剂量的有效性和安全性应该是未来研究的重点。该请求之所以引人入胜，是因为它为极其成功的抗病毒策略带来了希望；尽管如此，为了成功实施这种方法，可能有必要创建负担得起的配方和可扩展的解决方案,而不需要过度个体化治疗方案.由于它们具有抗炎和细胞保护作用的互补能力，因此,Akta和5-氨基水杨酸(5-ASA)施用可代表癌症治疗的显著进步。
